The good, the bad, and the ugly of luminex donor ‐specific crossmatch

The presence of donor‐specific antibodies directed against human leukocyte antigen significantly influences renal transplant because of antibody‐mediated rejection. We performed the screening of pre‐renal transplant patients for preformed anti‐HLA antibodies using anti‐human globulin augmented‐complement‐dependent lymphocytotoxicity crossmatch (AHG‐CDCXm), luminex donor‐specific crossmatch (LumXm) and HLA antibody screening. Seven hundred and fifty‐four patients were assessed for LumXm. HLA antibody screening was possible in 325 out of 754 cases. All the three investigations viz. CDCXm, HLA antibody screening and LumXm was performed in 325 patients. All CDCXm positive patients (10/325, 3.08%) were also positive with LumXm and HLA antibody screen whereas 14 cases (4.31%) with CDCXm negative were positive with luminex‐based assays. LumXm and HLA antibody screening were both positive in 24 (7.38%) cases, LumXm and HLA antibody screening were both negative in 275 (84.63%) cases and LumXm negative and HLA antibody screening was positive in 22 (6.76%) cases. However, there were four cases (1.23%) which were positive in LumXm in spite of being negative in HLA antibody testing. Single Antigen Bead (SAB) assay was performed in all patients positive for HLA antibody test. We suggest that LumXm is a useful and sensitive technique for the detection of anti‐HLA antibodies in pre‐transplant renal patients. However, other measures such as luminex antibody screen, S...
Source: Tissue Antigens - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research